A5088430170- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac electrophysiology and arrhythmias
- Heparin-Induced Thrombocytopenia and Thrombosis
- Heart Failure Treatment and Management
- Pharmaceutical Practices and Patient Outcomes
- Cardiac Arrhythmias and Treatments
- ECG Monitoring and Analysis
- Potassium and Related Disorders
Chonburi Hospital
2019-2023
Abstract Purpose This study aimed to describe incidence, risk factors, and outcomes of warfarin‐associated major bleeding (WAMB) in Thai patients. Method A nested case‐control was conducted a cohort adult patients receiving ≥6 months warfarin therapy who were prospectively followed up at tertiary care hospital Thailand during January 2011 December 2014. Logistic regression used identify factors associated with WAMB. The area under the receiver operating characteristic (AUROC) curve assess...
Drug-induced corrected QT (QTc) prolongation can cause Torsade de Pointes (TdP) which leads to severe arrhythmia or sudden cardiac death. However, information on the prevalence of QTc in coronavirus disease 2019 (COVID-19) patients and risk factors is limited. A retrospective chart review was conducted COVID-19 admitted Chonburi Hospital from April October 2020. The outcomes were incidence factor prolongation. We included 29 patients. After treatments initiated, occurred 17 (58.62%). could...
This study aimed to develop and validate a new bleeding risk score predict warfarin-associated major for patients with mitral valve stenosis atrial fibrillation (MSAF) or mechanical heart valves (MHV).A multicentre, retrospective cohort was conducted at 3 hospitals in Thailand. Adult MSAF MHV receiving warfarin ≥3 months during 2011-2015 were identified. Data collection case validation performed electronically manually. Potential variables screened using the least absolute shrinkage...
Initiating favipiravir in COVID-19 patients with long-term warfarin use can lead to increased INR. However, data on the onset and duration of increasing INR are limited.
OBJECTIVES: To determine the prevalence and characteristics of patients who achieved target doses angiotensin converting enzyme inhibitors (ACEIs)/ II receptor blockers (ARBs), beta-blocker, mineralocorticoid antagonists (MRAs). MATERIALS AND METHODS: A retrospective chart review study heart failure with reduced ejection fraction (HFrEF) received ACEIs/ARBs, beta-blockers, or MRAs follow-up more than four times at outpatient clinic, Chonburi hospital from February 1st, 2017 to 29th, 2020....